Scholar Rock Holding (SRRK) Interest Coverage Ratio (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Interest Coverage Ratio of 43.08 for Q1 2026, down 14.62% year-over-year from 50.46 in Q1 2025, and down 33.84% quarter-over-quarter from 32.19 in Q4 2025.
Scholar Rock Holding (SRRK) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Interest Coverage Ratio history runs 10 years deep, the most recent figure standing at 43.08 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 14.62% year-over-year to 43.08; the TTM figure through Mar 2026 stood at 46.08 (down 25.82% YoY), while the FY2025 annual figure was 2.07, down 141.06% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 43.08, down from 32.19 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.65 in Q3 2025, with the low at 57.68 in Q2 2022.
- The 5-year median for Interest Coverage Ratio is 21.83 (2024), against an average of 23.39.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio plunged 8814.95% in 2022, then surged 97.03% in 2025.
- Scholar Rock Holding's Interest Coverage Ratio stood at 24.24 in 2022, then rose by 0.67% to 24.08 in 2023, then slumped by 78.48% to 42.97 in 2024, then increased by 25.1% to 32.19 in 2025, then plunged by 33.84% to 43.08 in 2026.
- Business Quant data shows SRRK's Interest Coverage Ratio at 43.08 in Q1 2026, 32.19 in Q4 2025, and 0.65 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -0.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.53 |
| Mar 31, 2026 | -43.08 |
| Dec 31, 2025 | -32.19 |
| Sep 30, 2025 | -0.65 |
| Jun 30, 2025 | -0.72 |
| Mar 31, 2025 | -37.59 |
| Dec 31, 2024 | -42.97 |
| Sep 30, 2024 | -21.83 |
| Jun 30, 2024 | -16.86 |
| Mar 31, 2024 | -33.73 |
| Dec 31, 2023 | -24.08 |
| Sep 30, 2023 | -18.75 |
| Jun 30, 2023 | -13.01 |
| Mar 31, 2023 | -10.34 |
| Dec 31, 2022 | -24.24 |
| Sep 30, 2022 | -16.93 |
| Jun 30, 2022 | -57.68 |
| Mar 31, 2022 | -3.06 |
| Dec 31, 2021 | -60.14 |
| Sep 30, 2021 | -0.73 |